CanSino Biologics Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
1,494
- Stock Symbol
-
06185
- Investments
-
2
- Share Price
-
$4.01
- (As of Friday Closing)
CanSino Biologics General Information
Description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact Information
Website
www.cansinotech.comCorporate Office
- 401-420, 4th Floor, Biomedical Park
- 185 South Avenue, TEDA West District
- Tianjin
- China
Corporate Office
- 401-420, 4th Floor, Biomedical Park
- 185 South Avenue, TEDA West District
- Tianjin
- China
CanSino Biologics Stock Performance
As of 13-Dec-2024, CanSino Biologics’s stock price is $4.01. Its current market cap is $1.55B with 247M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.01 | $4.12 | $1.89 - $4.74 | $1.55B | 247M | 1.79M | -$0.49 |
CanSino Biologics Financials Summary
As of 30-Jun-2024, CanSino Biologics has a trailing 12-month revenue of $84.7M.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 714,190 | 1,282,612 | 2,898,675 | 7,560,903 |
| Revenue | 84,697 | 48,790 | 153,097 | 665,890 |
| EBITDA | (131,223) | (246,410) | (145,314) | 306,171 |
| Net Income | (120,432) | (209,577) | (135,040) | 296,479 |
| Total Assets | 1,119,185 | 1,314,613 | 1,662,337 | 1,862,881 |
| Total Debt | 302,294 | 380,941 | 391,435 | 215,688 |
CanSino Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CanSino Biologics Comparisons
Industry
Financing
Details
CanSino Biologics Competitors (33)
One of CanSino Biologics’s 33 competitors is Sinovac, a Corporation company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sinovac | Corporation | Beijing, China | ||||
| Novavax | Corporation | Gaithersburg, MD | ||||
| Novus Biologicals | Formerly PE-Backed | Centennial, CO | ||||
| 22nd Century Group | Corporation | Mocksville, NC | ||||
| GT Biopharma | Corporation | Brisbane, CA |
CanSino Biologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CanSino Biologics Patents
CanSino Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-3244837-U | Atomization cup and its use in atomization inhalation administration | Active | 29-Nov-2021 | ||
| JP-2023549995-A | Atomization cup and its use in atomization inhalation administration | Pending | 29-Nov-2021 | ||
| EP-4442302-A1 | Nebulizer cup and use thereof in nebulization inhalation administration | Pending | 29-Nov-2021 | ||
| EP-4151725-A1 | Method for preparing adenovirus vector vaccine by means of perfusion culture process | Pending | 09-Nov-2020 | ||
| CA-3182438-A1 | Method for preparing adenovirus vector vaccine by means of perfusion culture process | Pending | 09-Nov-2020 | C12N15/86 |
CanSino Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CanSino Biologics Investments (2)
CanSino Biologics’s most recent deal was a Early Stage VC with Bio-Link (Shanghai). The deal was made on 20-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bio-Link (Shanghai) | 20-Feb-2023 | Early Stage VC | Medical Supplies | ||
| Thousand Oaks Biopharmaceuticals | 30-Sep-2020 | Secondary Transaction - Private | Biotechnology |
CanSino Biologics ESG
Risk Overview
Risk Rating
Updated June, 07, 2024
25.52 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,100
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Pharmaceuticals
Subindustry
of 424
Rank
Percentile
CanSino Biologics FAQs
-
When was CanSino Biologics founded?
CanSino Biologics was founded in 2009.
-
Where is CanSino Biologics headquartered?
CanSino Biologics is headquartered in Tianjin, China.
-
What is the size of CanSino Biologics?
CanSino Biologics has 1,494 total employees.
-
What industry is CanSino Biologics in?
CanSino Biologics’s primary industry is Biotechnology.
-
Is CanSino Biologics a private or public company?
CanSino Biologics is a Public company.
-
What is CanSino Biologics’s stock symbol?
The ticker symbol for CanSino Biologics is 06185.
-
What is the current stock price of CanSino Biologics?
As of 13-Dec-2024 the stock price of CanSino Biologics is $4.01.
-
What is the current market cap of CanSino Biologics?
The current market capitalization of CanSino Biologics is $1.55B.
-
What is CanSino Biologics’s current revenue?
The trailing twelve month revenue for CanSino Biologics is $84.7M.
-
Who are CanSino Biologics’s competitors?
Sinovac, Novavax, Novus Biologicals, 22nd Century Group, and GT Biopharma are some of the 33 competitors of CanSino Biologics.
-
What is CanSino Biologics’s annual earnings per share (EPS)?
CanSino Biologics’s EPS for 12 months was -$0.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
